ArticleCancer2025

Efficacy, safety and predictive biomarker of third-generation tyrosine kinase inhibitors with azacitidine in myeloid blast phase of chronic myeloid leukemia.

Mei Bao et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.